Member Info for Novice14

Hugh doesn’t post on OPG power or WSG cattleman :-)

Shirley23 hehe I don’t personally although I have seen his passionate posts (especially his linking to Pfizer too!)

Haha thanks MC17 - I am indeed a novice at investing - am a pharmaceutical scientist by background and firmly believe in N4Ps prospects and the products on offer.

Couldn’t agree more patentpete that means a buyout could be on the cards too? The global vaccine market valuation is expected to exceed USD 77.5 billion by 2024 https://www.grandviewresearch.com/press-release/global-vaccine-market and it is projected that Pfizer’s market share will drop from 22% (2016) to 20.2% (2022) https://www.statista.com/statistics/348702/leading-global-pharmaceutical-companies-by-vaccine-market-share/ which is where N4P could help them consolidate their market share?

Detrusitol (Tolterodine) was marketed by Pfizer (after taking over Pharmacia & Upjohn) https://onlinelibrary.wiley.com/doi/pdf/10.1002/psb.863 and as soon as the parent ran out for the normal release preparation they launched a new modified release preparation with a new patent (Detrusitol XL) to maintain its stranglehold on market share. Similarly another of its drug Cardura (Doxazosin) was followed by an XL formulation as soon as the patent ran out again to maintain market share over the generics. With Viagra (Sildenafil) worldwide sales totaling $2.05 billion what makes us think Pfizer will turn a blind eye to an improved formulation that will ensure it continues its market stranglehold??!! N4P offers that very solution and result in multiples over current levels!!

“Global Erectile Dysfunction Market 2018-2023 - Market to Reach $4.25 Billion” https://www.businesswire.com/news/home/20180213006420/en/Global-Erectile-Dysfunction-Market-2018-2023---Market “Pfizer’s Viagra (sildenafil) still held a market-leading 47% share of the ED drug market in 2012, with worldwide sales totaling $2.05 billion“ + “Nonetheless, smart marketing can resonate with prescribers and patients. Since reaching pharmacy shelves in 2003, Lilly’s Cialis (tadalafil) has progressively taken share from Viagra, bringing home $1.9 billion in sales last year, according to regulatory filings. With a half-life of 17.5 hours—four times longer than that of Viagra—and a longer window of “responsiveness” (up to 36 hours), surveyed urologists believe Cialis offers patients with ED more freedom to choose when they participate in sexual intercourse“ https://www.forbes.com/sites/investor/2013/12/20/pfizers-expiring-viagra-patent-adversely-affects-other-drugmakers-too/#703f1d8a68d4 - which is exactly what N4P is targeting!! A better duration of action with rapid onset and less side-effects!!!

The first part of the N4Ps drug delivery formulation is via the sublingual route to enable rapid onset of action https://youtu.be/-25no8IVIyI - a published trial as already explored this and I firmly believe N4P and their formulation are a winner and they are on the right track - “drug tolerability through a likely modified pharmacokinetic, suggesting a possible implication also in the clinical efficacy profile. Sublingual administration of oro-dispersible formulations may represent a strategy to ameliorate the adherence to therapy with PDE5i, particularly in patients discouraged by side effects“ + “a remarkable drop-out from the treatment with PDE5i has been recently reported - in quantitative terms, an average discontinuation rate of 4% per month has been reported, with an overall abandonment of therapy in 50% cases on an annual basis. Among the main reasons given by patients to justify the abandonment of therapy, the lack of efficacy and side effects are referred as the most prevalent.” + “Since the occurrence of side effects increases with both serum levels and time exposure to the drug, the safety/efficacy profile of a drug can be alternatively improved through a pharmacokinetic approach by the design of a novel drug formulation.” https://www.frontiersin.org/articles/10.3389/fphar.2018.00059/full - N4Ps combined approach of using the sublingual and modified release approach is a winner!!

Sildenafil MR has already shown significant efficacy in previous trials reducing Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis https://www.ncbi.nlm.nih.gov/m/pubmed/21360507/ - N4Ps four way crossover study in 12 healthy subjects comparing N4 Pharma's reformulated 100mg sildenafil to Viagra 50mg in both fed and fasted conditions is beyond doubt in showing significant efficacy and superiority - the trial is just a matter of routine and will deliver fantastic results! Development of Controlled Release Sildenafil Formulations for Vaginal Administration has also been found to be useful https://www.tandfonline.com/doi/pdf/10.1080/10717540802006781 (different mode of delivery, nevertheless supports the N4P theory and provides an additional future market for N4Ps formulation!!)

Thanks Leistertheinvestor - couldn’t agree more Nuvec can solely blow the share price through the roof - research to follow

“intrinsic value of £0.34 OPG Power Ventures is quite good value at a 44.19% discount to what it is available for right now” published on the 10th of May before yesterdays positive RNS - surely has to be 50p?? Buy!!! https://simplywall.st/stocks/gb/utilities/aim-opg/opg-power-ventures-shares/news/investors-are-undervaluing-opg-power-ventures-plc-lonopg-by-44/

Thanks chalky230 - therefore only one way now considering we didn’t breach 19p and that is up? Can this do what Versarien did going from 20p to £1.20? With so many opportunities in the pipeline and rich news to follow I think it can!

Thanks applegarth will do - have more positive articles to share on the blockbuster opportunities for N4Ps Sildenfail MR formulation - will share these later too.

Yup can’t wait for the re-rate and final results!! :-) broker targets put this at 50p and comparatively Andes Energia (AEN) with a lower revenue and a higher loss is trading at 48p https://www.sharesmagazine.co.uk/shares/share/AEN

No previous name bongabob - am still a novice at trading :-)

Didn’t Nicola Duke say the next stop will be 46p/53p? https://youtu.be/Xk_VA_TfrDg (10:50 onwards)

Development of Controlled Release Sildenafil Formulations for Vaginal Administration has also been found to be useful https://www.tandfonline.com/doi/pdf/10.1080/10717540802006781 (different mode of delivery, nevertheless supports the N4P theory and provides an additional future market for N4Ps formulation!!)

Sildenafil MR has already shown significant efficacy in previous trials reducing Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis https://www.ncbi.nlm.nih.gov/m/pubmed/21360507/ - N4Ps four way crossover study in 12 healthy subjects comparing N4 Pharma's reformulated 100mg sildenafil to Viagra 50mg in both fed and fasted conditions is beyond doubt in showing significant efficacy and superiority - the trial is just a matter of routine and will deliver fantastic results!

https://uk.tradingview.com/symbols/LSE-N4P/technicals/ strong buy all round - get buying ......

“Six credit unions in southern Germany are still processing payments to Iran despite Washington’s withdrawal from the 2015 nuclear deal between Tehran and world powers and its impending new sanctions on Iran, a report said. While Germany’s big banks are avoiding Iran-related deals for fear of US reprisals, six credit unions, or Volksbanken, from southern Germany appear unafraid and are continuing to provide trade finance, according to the report carried by the Handelsblatt, a leading German-language business newspaper” + “But companies are still drawn to Iran’s promising market. Eighteen months ago, the six credit unions were helping 800 German firms to do business there. Melfi refused to reveal how many customers they still have, but she said they had received many inquiries from companies including several blue chips“ + “Melfi said her network could continue to settle transactions, even if the interbank messaging service SWIFT, which is used to transfer trillions of dollars between banks every day, were to stop transferring money to and from Iran. “We could maintain payments even without SWIFT and with the help of the Bundesbank,” she said, referring to the German central bank.” http://www.iran-bn.com/2018/06/02/german-credit-unions-stand-by-iran/

Appears to be business as usual - conference on opportunities in the Iranian Healthcare, Pharmaceutical, Life Sciences and Humanitarian sectors. Speakers include: Baroness Fairhead CBE, Minister of State for Trade and Export Promotion, DIT and The Rt Hon Lord Lamont of Lerwick, Chairman, BICC & UK Trade Envoy for Iran on 4th July in London http://www.bicc.org.uk/ev-healthcare_2018.html